Multiple myeloma<unk>  is used to treat multiple myeloma. It is a more potent molecular analog of thalidomide, which inhibits tumor angiogenesis, tumor-secreted cytokines, and tumor proliferation through induction of apoptosis.<unk>  is effective at inducing a complete or "very good partial" response and improves progression-free survival. Adverse events more common in people receiving<unk>  for myeloma include neutropenia, deep vein thrombosis, infections, and an increased risk of other hematological malignancies. The risk of second primary hematological malignancies does not outweigh the benefit of using<unk>  in relapsed or refractory multiple myeloma. It may be more difficult to mobilize stem cells for autograft in people who have received<unk> . In 2006,<unk>  received U.S. Food and Drug Administration (FDA) clearance for use in combination with dexamethasone in people with multiple myeloma who have received at least one prior therapy. In 2017, the FDA approved<unk>  as standalone maintenance therapy (without dexamethasone) for people with multiple myeloma following autologous stem cell transplant. In 2009, The National Institute for Health and Clinical Excellence issued a final appraisal determination approving<unk>  in combination with dexamethasone as an option to treat people with multiple myeloma who have received two or more prior therapies in England and Wales. The use of<unk>  combined with other drugs was evaluated. It was seen that the drug combinations of<unk>  plus dexamethasone and continuous bortezomib plus<unk>  plus dexamethasone probably result in an increase of the overall survival. Myelodysplastic syndromes<unk>  was approved by the FDA on 27 December 2005 for patients with low- or intermediate-1-risk myelodysplastic syndromes who have chromosome 5q deletion syndrome (5q- syndrome) with or without additional cytogenetic abnormalities. It was approved on 17 June 2013 by the European Medicines Agency for use in patients with low- or intermediate-1-risk myelodysplastic syndromes who have 5q- deletion syndrome but no other cytogenetic abnormalities and are dependent on red blood cell transfusions, for whom other treatment options have been found to be insufficient or inadequate. Mantle cell lymphoma<unk>  is approved by FDA as a specialty drug requiring a specialty pharmacy distribution for mantle cell lymphoma in patients whose disease has relapsed or progressed after at least two prior therapies, one of which must have included the medicine bortezomib. AL amyloidosis Although not specifically approved by the FDA for use in treating AL amyloidosis,<unk>  is widely used in the treatment of that condition, often in combination with dexamethasone.
Lenalidomide
Ruxolitinib
Pomalidomide
Vincristine
Bortezomib
Rituximab
Ibrutinib
Alemtuzumab